# Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

> **NCT00927862** · PHASE2,PHASE3 · COMPLETED · sponsor: **Intermountain Health Care, Inc.** · enrollment: 2415 (actual)

## Conditions studied

- Thromboembolism

## Interventions

- **GENETIC:** IWPC adapted genotype-guided dosing algorithm for warfarin
- **GENETIC:** Modified IWPC genetic-guided warfarin dosing algorithm
- **OTHER:** Standard of care treatment

## Key facts

- **NCT ID:** NCT00927862
- **Lead sponsor:** Intermountain Health Care, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-12
- **Final completion:** 2011-06
- **Target enrollment:** 2415 (ACTUAL)
- **Last updated:** 2012-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00927862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00927862, "Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00927862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*